Invalid Symbol

Stock Research for ANTH

Current Price


Latest Update:


Featured Broker: TradeStation

Get the due diligence for another stock.


ANTH Stock Chart & Research Data

The ANTH chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ANTH chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


ANTH Due diligence Resources & Stock Charts

The ANTH stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ANTH Detailed Price Forecast - CNN Money CNN View ANTH Detailed Summary - Google Finance
Yahoo View ANTH Detailed Summary - Yahoo! Finance Zacks View ANTH Stock Research & Analysis -

Stock Analysis

TradeIdeas View ANTH Trends & Analysis - Trade-Ideas Barrons View ANTH Major Holders - Barrons
NASDAQ View ANTH Call Transcripts - NASDAQ Seeking View ANTH Breaking News & Analysis - Seeking Alpha
Spotlight View ANTH Annual Report - OTC Report View ANTH OTC Short Report -
TradeKing View ANTH Fundamentals - TradeKing Charts View ANTH SEC Filings - Bar Chart
WSJ View Historical Prices for ANTH - The WSJ Morningstar View Performance/Total Return for ANTH - Morningstar
MarketWatch View the Analyst Estimates for ANTH - MarketWatch CNBC View the Earnings History for ANTH - CNBC
StockMarketWatch View the ANTH Earnings - StockMarketWatch MacroAxis View ANTH Buy or Sell Recommendations - MacroAxis
Bullish View the ANTH Bullish Patterns - American Bulls Short Pains View ANTH Short Pain Metrics -

Social Media Mentions

StockTwits View ANTH Stock Mentions - StockTwits PennyStocks View ANTH Stock Mentions - PennyStockTweets
Twitter View ANTH Stock Mentions - Twitter Invest Hub View ANTH Investment Forum News - Investor Hub
Yahoo View ANTH Stock Mentions - Yahoo! Message Board Seeking Alpha View ANTH Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for ANTH - Insider Cow View Insider Transactions for ANTH - Insider Cow
CNBC View ANTH Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ANTH - OTC Markets
Yahoo View Insider Transactions for ANTH - Yahoo! Finance NASDAQ View Institutional Holdings for ANTH - NASDAQ

Stock Charts

FinViz View ANTH Stock Insight & Charts - StockCharts View ANTH Investment Charts -
BarChart View ANTH Stock Overview & Charts - BarChart Trading View View ANTH User Generated Charts - Trading View

Latest Financial News for ANTH

Research Report Identifies Anthera Pharmaceuticals, Hancock Holding, MKS Instruments, Second Sight Medical Products, Eclipse Resources, and Aircastle with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
Posted on Monday March 19, 2018

NEW YORK, March 19, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

East Bay company's stock plummets 81% as drug for cystic fibrosis patients fails
Posted on Monday March 12, 2018

Anthera Pharmaceuticals Inc., which hung its hopes on a two-time loser treatment for cystic fibrosis patients, said the drug failed in a late-stage trial. Anthera President and CEO Craig Thompson said in a statement that the company was "greatly disappointed" by the results of the study. Anthera was positioning the drug as significant for patients with cystic fibrosis and other conditions, such as pancreatitis, whose pancreas can't produce three critical enzymes that move into the small intestine to help people carry out normal digestion.

East Bay company's stock plummets 81% as drug for cystic fibrosis patients fails
Posted on Monday March 12, 2018

Cystic fibrosis patients were hopeful that the drug could reduce their pill burden; instead a late-stage clinical trial failure caused Anthera Pharmaceutical's stock to dip as low as 40 cents per share.

Anthera Pharmaceuticals' stock plunges toward record low after failed drug trial
Posted on Monday March 12, 2018

Shares of Anthera Pharmaceuticals Inc. plummeted 84% in premarket trade Monday, after the biopharmaceutical company said it would suspend further development of Sollpura after a phase 3 study of exocrine ...

Warning: DOMDocument::load(): StartTag: invalid element name in, line: 1 in /home/allsites/ on line 494

Warning: DOMDocument::load(): Extra content at the end of the document in, line: 1 in /home/allsites/ on line 494

Enter a stock symbol to view the stock details.